GRI Bio (GRI)
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inf...
- Open
- 2.060
- High
- 2.220
- Low
- 1.890
- Prev. Close
- 2.200
- Volume
- 397.81K
- Turnover
- 814.50K
- Avg Price
- 2.047
- Bid/Ask Ratio
- -90.48%
- Amplitude
- 15.00%
- 52wk High
- 80.360
- Volume Ratio
- 18.21
- Turnover Ratio
- 80.61%
GRI Bio Analyst Rating
View moreForecast & Rating
Jun 1, 2026Price forecast
$21.00976.92%
Forecast & RatingStrong buy
2analysts
- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- benzinga_article · 1 day ago, 12:06 PM
12 Health Care Stocks Moving In Tuesday's Intraday Session
- benzinga_article · Jul 20 at 07:05 AM
12 Health Care Stocks Moving In Monday's Pre-Market Session
- StockTitan · Jun 17 at 11:31 PM
GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis | GRI Stock News
- benzinga_article · Jun 1 at 07:43 AM
Dell Technologies To Gain Nearly 79%? Here Are 10 Analyst Calls Investors Should Know
- StockTitan · May 18 at 12:15 AM
GRI Bio to Present at A.G.P.’s Annual Healthcare Company Showcase | GRI Stock News
- Tip Ranks · May 14 at 08:02 AM
GRI Bio Highlights Promising Phase 2a IPF Data, Outlook
